Issue 9, 2024

Advancing MRI with magnetic nanoparticles: a comprehensive review of translational research and clinical trials

Abstract

The nexus of advanced technology and medical therapeutics has ushered in a transformative epoch in contemporary medicine. Within this arena, Magnetic Resonance Imaging (MRI) emerges as a paramount tool, intertwining the advancements of technology with the art of healing. MRI's pivotal role is evident in its broad applicability, spanning from neurological diseases, soft-tissue and tumour characterization, to many more applications. Though already foundational, aspirations remain to further enhance MRI's capabilities. A significant avenue under exploration is the incorporation of innovative nanotechnological contrast agents. Forefront among these are Superparamagnetic Iron Oxide Nanoparticles (SPIONs), recognized for their adaptability and safety profile. SPION's intrinsic malleability allows them to be tailored for improved biocompatibility, while their functionality is further broadened when equipped with specific targeting molecules. Yet, the path to optimization is not devoid of challenges, from renal clearance concerns to potential side effects stemming from iron overload. This review endeavors to map the intricate journey of SPIONs as MRI contrast agents, offering a chronological perspective of their evolution and deployment. We provide an in-depth current outline of the most representative and impactful pre-clinical and clinical studies centered on the integration of SPIONs in MRI, tracing their trajectory from foundational research to contemporary applications.

Graphical abstract: Advancing MRI with magnetic nanoparticles: a comprehensive review of translational research and clinical trials

Article information

Article type
Review Article
Submitted
29 11 2023
Accepted
01 4 2024
First published
02 4 2024
This article is Open Access
Creative Commons BY license

Nanoscale Adv., 2024,6, 2234-2259

Advancing MRI with magnetic nanoparticles: a comprehensive review of translational research and clinical trials

R. Lapusan, R. Borlan and M. Focsan, Nanoscale Adv., 2024, 6, 2234 DOI: 10.1039/D3NA01064C

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements